Genmab Revenue and Competitors
Estimated Revenue & Valuation
- Genmab's estimated annual revenue is currently $7.9B per year.
- Genmab received $10.0M in venture funding in October 2014.
- Genmab's estimated revenue per employee is $2,841,236
- Genmab's total funding is $204.3M.
- Genmab's current valuation is $23.5B. (January 2022)
Employee Data
- Genmab has 2784 Employees.
- Genmab grew their employee count by 6% last year.
Genmab's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CMO EVP Head Experimental Medicine | Reveal Email/Phone |
2 | SVP Legal/IPR | Reveal Email/Phone |
3 | SVP, Investor Relations and Communications | Reveal Email/Phone |
4 | SVP Strategic Initiatives | Reveal Email/Phone |
5 | VP, Head US Medical Affairs | Reveal Email/Phone |
6 | SVP, Information Technology and Digital | Reveal Email/Phone |
7 | VP, Global Marketing | Reveal Email/Phone |
8 | SVP, Head Operations R&D | Reveal Email/Phone |
9 | VP, Operations & Resource Management | Reveal Email/Phone |
10 | VP, Head Research operations | Reveal Email/Phone |
Genmab Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7910M | 2784 | 6% | $204.3M | N/A |
#2 | $42.8M | 276 | 8% | N/A | N/A |
#3 | $3.4M | 1097 | -1% | $85.7M | N/A |
#4 | $13.2M | 12 | -77% | $263.3M | N/A |
#5 | $22.9M | 148 | 17% | N/A | N/A |
#6 | $3.6M | 23 | 10% | N/A | N/A |
#7 | $28.5M | 184 | 37% | N/A | N/A |
#8 | $1.6M | 10 | -17% | N/A | N/A |
#9 | $10.1M | 65 | 35% | N/A | N/A |
#10 | $9.1M | 59 | 59% | N/A | N/A |
What Is Genmab?
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Disclaimer: bit.ly/GENDisclaimer
keywords:N/A
$204.3M
Total Funding
2784
Number of Employees
$7.9B
Revenue (est)
6%
Employee Growth %
$23.5B
Valuation
N/A
Accelerator
Genmab News
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. ... To develop and deliver novel...
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to...
AbbVie and Genmab are co-developing epcoritamab as part of the companies' broader oncology collaboration deal. "Together with our partner,...
Precision medicine company Tempus, and antibody therapeutics company Genmab announced have announced a strategic collaboration that ...
Genmab Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-10-27 | $10.0M | Undisclosed | Janssen Biotech Inc | Article |